Molecular Dynamics MegaBACE 1000 DNA sequencer sales ramp-up depends on initial market acceptance.
This article was originally published in The Gray Sheet
Executive SummaryMOLECULAR DYNAMICS MEGABACE 1000 DNA SEQUENCER FULL-SCALE LAUNCH is contingent on the level of market acceptance in the second phase of the company's three-stage roll-out strategy, the company says. "During the latter part of 1998, we will go into the broader market launch of this product, but that will depend on the level of demand we experience in" the ongoing phase-two marketing, President and CEO Jay Flatley told investors at a Jan. 12 session of the Hambrecht & Quist health care conference in San Francisco.
Register for our free email digests: